Boji Medical Technology Co.,Ltd.

SZSE:300404 Stock Report

Market Cap: CN¥3.3b

Boji Medical TechnologyLtd Past Earnings Performance

Past criteria checks 4/6

Boji Medical TechnologyLtd has been growing earnings at an average annual rate of 21.5%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 25.3% per year. Boji Medical TechnologyLtd's return on equity is 4.7%, and it has net margins of 5.9%.

Key information

21.5%

Earnings growth rate

18.0%

EPS growth rate

Life Sciences Industry Growth26.8%
Revenue growth rate25.3%
Return on equity4.7%
Net Margin5.9%
Last Earnings Update30 Sep 2024

Recent past performance updates

We Don’t Think Boji Medical TechnologyLtd's (SZSE:300404) Earnings Should Make Shareholders Too Comfortable

Nov 02
We Don’t Think Boji Medical TechnologyLtd's (SZSE:300404) Earnings Should Make Shareholders Too Comfortable

Boji Medical TechnologyLtd's (SZSE:300404) Profits Appear To Have Quality Issues

May 01
Boji Medical TechnologyLtd's (SZSE:300404) Profits Appear To Have Quality Issues

Recent updates

We Don’t Think Boji Medical TechnologyLtd's (SZSE:300404) Earnings Should Make Shareholders Too Comfortable

Nov 02
We Don’t Think Boji Medical TechnologyLtd's (SZSE:300404) Earnings Should Make Shareholders Too Comfortable

A Piece Of The Puzzle Missing From Boji Medical Technology Co.,Ltd.'s (SZSE:300404) 39% Share Price Climb

Oct 08
A Piece Of The Puzzle Missing From Boji Medical Technology Co.,Ltd.'s (SZSE:300404) 39% Share Price Climb

Boji Medical TechnologyLtd's (SZSE:300404) Profits Appear To Have Quality Issues

May 01
Boji Medical TechnologyLtd's (SZSE:300404) Profits Appear To Have Quality Issues

Further Upside For Boji Medical Technology Co.,Ltd. (SZSE:300404) Shares Could Introduce Price Risks After 35% Bounce

Mar 06
Further Upside For Boji Medical Technology Co.,Ltd. (SZSE:300404) Shares Could Introduce Price Risks After 35% Bounce

Revenue & Expenses Breakdown

How Boji Medical TechnologyLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300404 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 247534514563
30 Jun 246653713758
31 Mar 246202913056
31 Dec 235562412455
30 Sep 235042911751
30 Jun 234813011248
31 Mar 234532710845
01 Jan 234242810444
30 Sep 22388279837
30 Jun 22379409534
31 Mar 22343448730
01 Jan 22324398028
30 Sep 21298317430
30 Jun 21271197128
31 Mar 21295306728
31 Dec 20260176726
30 Sep 20259206423
30 Jun 20241166222
31 Mar 20209-16621
31 Dec 1922476718
30 Sep 1920176716
30 Jun 1918956115
31 Mar 1917745713
31 Dec 1817275413
30 Sep 18155-166013
30 Jun 18153-195416
31 Mar 18152-165213
31 Dec 17131-245110
30 Sep 17121-3457
30 Jun 171034500
31 Mar 1774-1470
31 Dec 16722450
30 Sep 168111400
30 Jun 168812400
31 Mar 1611122380
31 Dec 1512726370
30 Sep 1515039300
30 Jun 1515339290
31 Mar 1514839280
31 Dec 1414438270
31 Dec 1313635220

Quality Earnings: 300404 has a large one-off gain of CN¥14.4M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300404's current net profit margins (5.9%) are higher than last year (5.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300404's earnings have grown significantly by 21.5% per year over the past 5 years.

Accelerating Growth: 300404's earnings growth over the past year (52.3%) exceeds its 5-year average (21.5% per year).

Earnings vs Industry: 300404 earnings growth over the past year (52.3%) exceeded the Life Sciences industry -14.4%.


Return on Equity

High ROE: 300404's Return on Equity (4.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies